Endpoints News 生物医药· Lei Lei Wu·· 2026-10-09AI 评分56
Revolution Medicines的Rasonque胰腺癌新数据:常见KRAS突变患者响应率或低于总体人群
New data on RevMed’s Rasonque leave potential opening for other treatments
AI 导读
接受Revolution Medicines的Rasonque治疗的胰腺癌患者中,携带最常见KRAS突变的患者响应率似乎低于总体人群;报道认为这或为其他治疗留下空间。
正文
Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient population with Revolution Medicines’ Rasonque …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news